Long Non-coding RNAs in Myeloid Malignancies
Acute myeloid leukemia (AML) represents 80% of adult leukemias and 15–20% of childhood leukemias. AML are characterized by the presence of 20% blasts or more in the bone marrow, or defining cytogenetic abnormalities. Laboratory diagnoses of myelodysplastic syndromes (MDS) depend on morphological changes based on dysplasia in peripheral blood and bone marrow, including peripheral blood smears, bone marrow aspirate smears, and bone marrow biopsies. As leukemic cells are not functional, the patient develops anemia, neutropenia, and thrombocytopenia, leading to fatigue, recurrent infections, and hemorrhage. The genetic background and associated mutations in AML blasts determine the clinical course of the disease. Over the last decade, non-coding RNAs transcripts that do not codify for proteins but play a role in regulation of functions have been shown to have multiple applications in the diagnosis, prognosis and therapeutic approach of various types of cancers, including myeloid malignancies. After a comprehensive review of current literature, we found reports of multiple long non-coding RNAs (lncRNAs) that can differentiate between AML types and how their exogenous modulation can dramatically change the behavior of AML cells. These lncRNAs include: H19, LINC00877, RP11-84C10, CRINDE, RP11848P1.3, ZNF667-AS1, AC111000.4-202, SFMBT2, LINC02082-201, MEG3, AC009495.2, PVT1, HOTTIP, SNHG5, and CCAT1. In addition, by performing an analysis on available AML data in The Cancer Gen...
Publication date: Available online 3 April 2020Source: Journal of Orthopaedic TranslationAuthor(s): Litao Yan, Gejun Liu, Xing Wu
CONCLUSIONS: Our findings support the protective effect a normal weight against advanced adenomas. Reduction of BMI value should be pursued in healthy programs. PMID: 32233893 [PubMed - as supplied by publisher]
Conclusion: There is a slightly increasing trend in the occurrence of esophageal perforations. Contemporary treatment is less invasive with similar results. Patients treated in high-volume hospitals have better prognosis. PMID: 32233883 [PubMed - as supplied by publisher]
In conclusion, this ESRI technique combined with MRI, may offer a powerful clinical tool to noninvasively detect variable hypoxic status in tumors and to identify a window of vascular renormalization to maximize the effects of combination therapy with antiangiogenic drugs. PMID: 32238677 [PubMed - as supplied by publisher]
More than one fifth of patients who are treated for gynecologic malignancies experience financial toxicity, results of a single-center study suggest.
Results of a systematic review and meta-analysis support a possible role for osimertinib in the management of non-small-cell lung cancer (NSCLC) patients with intracranial metastatic disease, researchers say.Reuters Health Information
Authors: Montemurro F, Nuzzolese I, Ponzone R Abstract Introduction: The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field.Areas covered: Herein, the authors cover neoadjuvant chemotherapy with or without biologics in triple-negative and HER2-positive operable breast cancer with a focus on rates of complete pathological remission (pCR) in the breast and axilla. The impact of the CREATE X and KATERINE randomi...
One of the biggest challenges of this unsettling time is the isolation we feel as we’re separated from friends and family, all the people for whom we care most deeply. But just being alone is only part of the difficulty. Our sense of remoteness is intensified by a pall of unease we can’t define: Loss and sorrow are also in the air. We fear losing—or we may have already lost—people we love. And when we work up the courage to look beyond our individual personal spheres, we see that many people who have made our world better, in big and small ways, have vanished before we were ready to let them go. But...
Publication date: Available online 2 April 2020Source: Saudi Pharmaceutical JournalAuthor(s): Md. Salman Akhtar, Naseem Akhter, Mohammad Zeeshan Najm, SVS Deo, NK Shukla, Shaia Saleh R. Almalki, Raed A. Alharbi, Abdulmajeed Abdulghani A. Sindi, Abdulmohsen Alruwetei, Abrar Ahmad, Syed Akhtar Husain
Dr Mark Kris discusses the profound effect that the wait time between cancer being diagnosed and treatment being initiated has on both patients and physicians.Medscape Oncology
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Chemotherapy | Childhood Cancer | Genetics | Laboratory Medicine | Leukemia | Myelodysplastic Syndrome | Papanicolaou (Pap) Smear | Stem Cell Therapy | Stem Cells | Thrombocytopenia | Transplants